Cargando…

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

Detalles Bibliográficos
Autores principales:	Koumarianou, Anna, Antoniou, Stavroula, Kanakis, George, Economopoulos, Nikolaos, Rontogianni, Dimitra, Ntavatzikos, Anastasios, Tsavaris, Nikolaos, Pectasides, Dimitrios, Dimitriadis, George, Kaltsas, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Endocrinology 2012
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255566/ https://www.ncbi.nlm.nih.gov/pubmed/22232542 http://dx.doi.org/10.1530/ERC-11-0287

Ejemplares similares

Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Koumarianou, Anna, et al.
Publicado: (2020)

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
por: Berruti, Alfredo, et al.
Publicado: (2014)

The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
por: Koumarianou, Anna, et al.
Publicado: (2014)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature
por: Tsoukalas, Nikolaos, et al.
Publicado: (2017)

Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
por: Dutta, Pinaki, et al.
Publicado: (2019)

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019)

Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer
por: Kampoli, Katerina, et al.
Publicado: (2022)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2019)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

Current best practice in the management of neuroendocrine tumors
por: Tsoli, Marina, et al.
Publicado: (2018)

Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors
por: Koumarianou, Anna, et al.
Publicado: (2019)

A Pleomorphic Rhabdomyosarcoma Mimicking an Inguinal Hernia: A Case Report and Review of the Literature
por: Koumarianou, Anna, et al.
Publicado: (2012)

Role of stress, age and adjuvant therapy in the cognitive function of patients with breast cancer
por: Papanastasiou, Artemis, et al.
Publicado: (2019)

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report
por: Peristeri, Dimitra V., et al.
Publicado: (2021)

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2016)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016)

Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer
por: Koumarianou, Anna, et al.
Publicado: (2020)

Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
por: Tena, Isabel, et al.
Publicado: (2018)

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
por: Büsker, Sören, et al.
Publicado: (2022)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
por: Alagkiozidis, Ioannis, et al.
Publicado: (2015)

Atypical manifestation of parathyroid carcinoma with late-onset distant metastases
por: Tsoli, Marina, et al.
Publicado: (2017)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
por: Pectasides, Dimitrios, et al.
Publicado: (2012)

Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
por: Exner, Samantha, et al.
Publicado: (2018)

Heterogeneity of Small Intestinal Neuroendocrine Tumors Metastasis: Biologic Patterns of a Series with Virchow’s Node Involvement
por: Wedin, Maria, et al.
Publicado: (2022)

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer
por: Kelley, R K, et al.
Publicado: (2013)

Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
por: Ouyang, Mao, et al.
Publicado: (2016)

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
por: Kvols, L. K., et al.
Publicado: (1992)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors
por: Lubner, Sam, et al.
Publicado: (2018)

Currently available treatment options for neuroendocrine liver metastases
por: Machairas, Nikolaos, et al.
Publicado: (2021)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
por: Chauhan, Aman, et al.
Publicado: (2018)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2018)

Transurethral resection of a bladder trigone leiomyoma: a rare case report
por: Zachariou, Athanasios, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jmlcvovm11frlvlm7r33jpdkri